Company announces positive long-term data for two-drug HIV regimen dolutegravir sodium and lamivudine (Dovato®)

The company announced week 96 findings from the TANGO study showed that switching to Dovato was as good as continuing on a tenofovir alafenamide fumarate based regimen in the intention to treat-exposed analysis, defined as all participants randomised to the study.

Source:

PharmaTimes